Kymeris Therapeutics
Kymeris Therapeutics is a pre-clinical immuno-oncology company focused on developing a novel platform technology to improve solid cancer cure rates. Their unique platform involves engineered eukaryotic cells derived from a non-pathogenic protozoan, Neospora, which infiltrate and reprogram the tumor microenvironment to turn cold tumors hot, enabling complex molecular therapies to be delivered directly into tumors. The company aims to advance clinical development in the US and reinforce platform research in Europe, with a mission to transform outcomes in solid cancers through multifunctional, tumor-tropic immunotherapeutic delivery.
Industries
Nr. of Employees
small (1-50)
Kymeris Therapeutics
Patents
Products
Genetically engineered eukaryotic cellular therapy platform
A preclinical cell‑based platform derived from a non‑pathogenic eukaryotic cell type, engineered to home to and penetrate the TME, reprogram immune suppression, deliver multiple transgenic payloads (surface or secreted), enter cancer cells, and induce oncolysis and neoantigen release.
Genetically engineered eukaryotic cellular therapy platform
A preclinical cell‑based platform derived from a non‑pathogenic eukaryotic cell type, engineered to home to and penetrate the TME, reprogram immune suppression, deliver multiple transgenic payloads (surface or secreted), enter cancer cells, and induce oncolysis and neoantigen release.
Services
Collaborative development and licensing of the cell‑based delivery platform to enable delivery of partner proprietary molecules into the tumor microenvironment.
Collaborative development and licensing of the cell‑based delivery platform to enable delivery of partner proprietary molecules into the tumor microenvironment.
Expertise Areas
- Cell‑based therapeutics
- Tumor microenvironment modulation
- Immuno‑oncology and Th1 immune activation
- Transgenic payload engineering (surface and secreted expression)
Key Technologies
- Genetically engineered eukaryotic cellular vectors
- Tumor‑tropic cell‑based delivery
- Transgenic payload expression (surface display and secretion)
- Intracellular replication and oncolytic mechanism